Kitov Announces U.S. FDA Acceptance of Investigational New Drug Application to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer Patients
May 22, 2020 07:00 ET
|
Kitov Pharma Ltd.
Company to Evaluate NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head and Neck Cancer in a Phase...
Kitov Announces U.S. Commercial Launch of Consensi™
May 20, 2020 07:30 ET
|
Kitov Pharma Ltd.
TEL AVIV, Israel, May 20, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting II
May 19, 2020 08:05 ET
|
Kitov Pharma Ltd.
Company Expects to Initiate Phase 1/2 Trial of NT-219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head...
Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at American Society of Clinical Oncology 2020 Virtual Scientific Program
May 14, 2020 07:10 ET
|
Kitov Pharma Ltd.
Company Expects to Initiate Phase 1/2 Clinical trial, in Collaboration with Bristol Myers Squibb, with CM-24 in Combination with nivolumab (Opdivo®) in Second Half of 2020 TEL AVIV, Israel, May...
Kitov Closes $10 Million Registered Direct Offering
May 08, 2020 16:00 ET
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, May 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Announces $10 million Registered Direct Offering
May 06, 2020 08:00 ET
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, May 06, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants
April 20, 2020 08:05 ET
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, April 20, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion...
Kitov Closes $6.0 Million Public Offering
March 17, 2020 08:00 ET
|
Kitov Pharma Ltd.
TEL-AVIV, March 17, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug...
Kitov Pharma Provides Update on Planned U.S. Launch of Consensi™ and Provides Three-Year Revenue Forecast
March 12, 2020 08:15 ET
|
Kitov Pharma Ltd.
Company’s marketing partners in the U.S. plan to commence selling Consensi in May 2020Kitov expects to receive between $28 million and $36 million in milestone and royalty revenues from 2020 through...
Kitov Announces Pricing of $6.0 Million Public Offering
March 12, 2020 08:00 ET
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...